Tokushima, Japan

Takashi Shiroi

This inventor holds 33 USPTO granted patents, primarily in Beta-Lactam Chemistry. Top assignees: Otsuka Kagaku Kabushiki Kaisha, Otsuka Kagaku Yakuhin Kabushiki Kaisha, Otsuke Kagaku Yakuhin Kabushiki Kaisha. Active years: 1983-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takashi Shiroi. Retrieved from https://idiyas.com/inventor/takashi-shiroi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.6

ph-index = 7

Forward Citations = 163(Granted Patents)


Location History:

  • Okayama, JP (1983 - 1989)
  • Itano, JP (1987 - 1995)
  • Tokushima, JP (1986 - 1997)
  • Tokushima-ken, JP (1997)
  • Itano-gun, JP (1997 - 1998)

Company Filing History:


Years Active: 1983-1998

Loading Chart...
Areas of Expertise:
Beta-Lactam
Cephem Compounds
Azetidinone Derivatives
Thiazolinoazetidinone
Penam Derivatives
Chemical Processes
Bicyclic Intermediates
Thiazolidine Compounds
Oxazolineazetidinone
3-Substituted Compounds
Production Methods
Chemical Derivatives
33 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Takashi Shiroi in Pharmaceutical Patents**

Introduction

Takashi Shiroi, hailing from Tokushima, Japan, is a notable inventor with an impressive portfolio of 33 patents. His work primarily focuses on enhancing pharmaceutical compounds, especially in the field of antibiotics. Through his innovative approach, he has made significant strides in the development of crucial pharmaceutical intermediates.

Latest Patents

One of Shiroi's latest patents includes the invention of an ozonide reducing agent as well as a beta-lactam and cephem compound. This invention aims to provide a beta-lactam compound and a 2-substituted methyl-3-cephem compound, both of which are valuable as intermediates for synthesizing cephem antibiotics. The beta-lactam compound is represented by a specific general formula where R^1 denotes a protected amino group, R^2 represents hydrogen, R^3 is either hydrogen or a carboxy-protecting group, R^4 is an aryl group that may be substituted, and R^5 is a substitutable alkenyl group. Additionally, the cephem compound is characterized by variable R groups that further enhance its pharmaceutical potential.

Career Highlights

Throughout his career, Takashi Shiroi has collaborated with esteemed companies such as Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Factory, Inc. His experience in these organizations has undoubtedly contributed to his expertise in the pharmaceutical field, enabling him to navigate complex innovation landscapes and produce significant inventions.

Collaborations

In his inventive journey, Shiroi has worked alongside notable colleagues like Hideo Tanaka and Michio Sasaoka. These collaborations have played a vital role in fostering innovation and pushing the boundaries of pharmaceutical science.

Conclusion

Takashi Shiroi's contributions to the field of pharmaceuticals are commendable, with a focus on innovative compounds that serve as vital intermediates in antibiotic synthesis. His extensive patent portfolio is a testament to his dedication and ingenuity, making him a distinguished figure in the realm of pharmaceutical inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…